Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.37 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769014 | 1.00 | AHR (0.48) | AHRNOTUMHSD17B10RAPGEF4ALDH1A1 | |
| SCHEMBL18002403 | 0.89 | AHR (0.56) | AHRNOTUMHSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL18002341 | 0.85 | NOTUM (0.44) | AHRNOTUMHSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL6856533 | 0.84 | CES2 (0.41) | AHRALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL66819 | 0.84 | CES2 (0.46) | ALDH1A1CES2RPS6KA3JAK3KIF11 | |
| SCHEMBL19137556 | 0.84 | AHR (0.38) | AHRNOTUMHSD17B10ALDH1A1ERN1 | |
| SCHEMBL15459066 | 0.81 | AHR (0.36) | AHRHSD17B10ERN1 | |
| SCHEMBL15459373 | 0.81 | AHR (0.36) | AHRHSD17B10ALDH1A1ERN1 | |
| SCHEMBL27856971 | 0.80 | AHR (0.46) | AHRNOTUMRAPGEF4ALDH1A1CYP3A4 | |
| SCHEMBL19137700 | 0.80 | AHR (0.35) | AHRHSD17B10ALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390336-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2004-02-25 | — | — | EP | claimed |
| WO-2002096849-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2002-12-05 | — | — | WO | claimed |
| US-20250262205-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12318383-B2 | Dual MAGL and FAAH inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250049806-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | UBE CORP (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4431098-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | UBE Corporation (JP) | 2024-09-18 | — | — | EP | disclosed |
| EP-4424683-A2 | DUAL MAGL AND FAAH INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3595665-B1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118271288-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117736178-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4335848-A2 | DUAL MAGL AND FAAH INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-1972932-B | Compounds for the treatment of dyslipidemia | LILLY CO ELI | 2011-06-29 | — | — | CN | disclosed |
| WO-2010119992-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | WO | disclosed |
| US-7786108-B2 | Compounds and method for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| CN-1972932-A | Compounds and methods for treating dyslipidemia | LILLY CO ELI (US) | 2007-05-30 | — | — | CN | disclosed |
| US-4112095-A | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents | AMERICAN CYANAMID COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | AHR 1815/4885NOTUM 1955/4885HSD17B10 4701/4885 |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | CETP, APOB, MTTP | AHR 3969/4885NOTUM 731/4885HSD17B10 2120/4885 |
| US-20250262205-A1 | DUAL MAGL AND FAAH INHIBITORS | FAAH, FAAH2, MAG | AHR 1762/4885NOTUM 769/4885HSD17B10 2796/4885 |
| US-12318383-B2 | Dual MAGL and FAAH inhibitors | FAAH, FAAH2, MAG | AHR 1762/4885NOTUM 769/4885HSD17B10 2796/4885 |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | APOB, LIPC, PCSK9 | AHR 3547/4885NOTUM 348/4885HSD17B10 180/4885 |
| US-20250049806-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | CYP21A2, HSD11B2, MC2R | AHR 162/4885NOTUM 936/4885HSD17B10 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.